The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Targeting cellular metabolism to improve cancer therapeutics
Open accessAbstract
The metabolic properties of cancer cells diverge significantly from those of normal cells. Energy production in cancer cells is abnormally dependent on aerobic glycolysis. In addition to the dependency on glycolysis, cancer cells have other atypical metabolic characteristics such as increased fatty acid synthesis and increased rates of glutamine metabolism. Emerging evidence shows that many features characteristic to cancer cells, such as dysregulated Warburg-like glucose metabolism, fatty acid synthesis and glutaminolysis are linked to therapeutic resistance in cancer treatment. Therefore, targeting cellular metabolism may improve the response to cancer therapeutics and the combination of chemotherapeutic drugs with cellular metabolism inhibitors may represent a promising strategy to overcome drug resistance in cancer therapy. Recently, several review articles have summarized the anticancer targets in the metabolic pathways and metabolic inhibitor-induced cell death pathways, however, the dysregulated metabolism in therapeutic resistance, which is a highly clinical relevant area in cancer metabolism research, has not been specifically addressed. From this unique angle, this review article will discuss the relationship between dysregulated cellular metabolism and cancer drug resistance and how targeting of metabolic enzymes, such as glucose transporters, hexokinase, pyruvate kinase M2, lactate dehydrogenase A, pyruvate dehydrogenase kinase, fatty acid synthase and glutaminase can enhance the efficacy of common therapeutic agents or overcome resistance to chemotherapy or radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mitochondrial Autophagy Is an HIF-1-dependent Adaptive Metabolic Response to Hypoxia
Zhang, H., Bosch-Marce, M., Shimoda, L. A., Tan, Y. S., Baek, J. H., Wesley, J. B., Gonzalez, F. J., & Semenza, G. L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800102200 · Cited by 1,601
RetractedUnderstanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Why Do Cancers Have High Aerobic Glycolysis?
Gatenby, R. A., & Gillies, R. J. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1478 · Cited by 4,784
The BCL-2 protein family: opposing activities that mediate cell death
Youle, R. J., & Strasser, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2308 · Cited by 4,679
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation
DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., & Thompson, C. B. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.10.002 · Cited by 4,088
On Respiratory Impairment in Cancer Cells
Warburg, O. (1956) · Science · doi:10.1126/science.124.3215.269 · Cited by 3,468
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
DeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622
Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1
Ceradini, D. J., Kulkarni, A. R., Callaghan, M. J., Tepper, O. M., Bastidas, N., Kleinman, M. E., Capla, J. M., Galiano, R. D., Levine, J. P., & Gurtner, G. C. (2004) · Nature Medicine · doi:10.1038/nm1075 · Cited by 2,600
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Cancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
Glutamine addiction: a new therapeutic target in cancer
Wise, D. R., & Thompson, C. B. (2010) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.05.003 · Cited by 1,770
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Fantin, V. R., St-Pierre, J., & Leder, P. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.023 · Cited by 1,635
Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
Glycolysis inhibition for anticancer treatment
Pelicano, H., Martin, D. S., Xu, R.-H., & Huang, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209597 · Cited by 1,516
Hypoxia-inducible expression of tumor-associated carbonic anhydrases.
Wykoff, C. C., Beasley, N. J. P., Watson, P. H., Turner, K., Pastorek, J., Sibtain, A., Wilson, G. D., Turley, H., Talks, K., Maxwell, P. H., et al. (2000) · PubMed · Cited by 1,491
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
Pennacchietti, S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., & Comoglio, P. M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00085-0 · Cited by 1,311
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer
Macheda, M. L., Rogers, S., & Best, J. D. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20166 · Cited by 1,229
Cancer's Molecular Sweet Tooth and the Warburg Effect
Kim, J.-W., & Dang, C. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1501 · Cited by 1,215
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Brick by brick: metabolism and tumor cell growth
DeBerardinis, R. J., Sayed, N., Ditsworth, D., & Thompson, C. B. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.02.003 · Cited by 1,018
Links between metabolism and cancer
Dang, C. V. (2012) · Genes & Development · doi:10.1101/gad.189365.112 · Cited by 998
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
Nahta, R., Yu, D., Hung, M.-C., Hortobagyi, G. N., & Esteva, F. J. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0509 · Cited by 916
(2002) · PubMed · Cited by 840
Heat Shock Factor 1 Is a Powerful Multifaceted Modifier of Carcinogenesis
Dai, C., Whitesell, L., Rogers, A. B., & Lindquist, S. (2007) · Cell · doi:10.1016/j.cell.2007.07.020 · Cited by 826
Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Wang, J.-B., Erickson, J. W., Fuji, R., Ramachandran, S., Gao, P., Dinavahi, R., Wilson, K. F., Ambrosio, A. L. B., Dias, S. M. G., Dang, C. V., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.08.009 · Cited by 821
Tyrosine Phosphorylation Inhibits PKM2 to Promote the Warburg Effect and Tumor Growth
Hitosugi, T., Kang, S., Vander Heiden, M. G., Chung, T.-W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., et al. (2009) · Science Signaling · doi:10.1126/scisignal.2000431 · Cited by 784
Glutaminolysis Activates Rag-mTORC1 Signaling
Durán, R. V., Oppliger, W., Robitaille, A. M., Heiserich, L., Skendaj, R., Gottlieb, E., & Hall, M. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.043 · Cited by 730
The Stem Cell Marker Bcrp/ABCG2 Enhances Hypoxic Cell Survival through Interactions with Heme
Krishnamurthy, P., Ross, D. D., Nakanishi, T., Bailey-Dell, K., Zhou, S., Mercer, K. E., Sarkadi, B., Sorrentino, B. P., & Schuetz, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313599200 · Cited by 661
Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer
Michelakis, E. D., Webster, L., & Mackey, J. R. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604554 · Cited by 656
Causes and Consequences of Increased Glucose Metabolism of Cancers
Gillies, R. J., Robey, I., & Gatenby, R. A. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.047258 · Cited by 623
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
Fatty Acid Synthase As a Potential Therapeutic Target in Cancer
Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M. (2010) · Future Oncology · doi:10.2217/fon.10.11 · Cited by 545
Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, M. J., Bennett, B. D., Joshi, A. D., Gao, P., Thomas, A. G., Ferraris, D. V., Tsukamoto, T., Rojas, C. J., Slusher, B. S., Rabinowitz, J. D., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1666 · Cited by 513
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Erler, J. T., Cawthorne, C. J., Williams, K. J., Koritzinsky, M., Wouters, B. G., Wilson, C., Miller, C., Demonacos, C., Stratford, I. J., & Dive, C. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2875-2889.2004 · Cited by 400
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
Self-citationCancer metabolism: current perspectives and future directions
Muñoz-Pinedo, C., El Mjiyad, N., & Ricci, J.-E. (2012) · Cell Death & Disease · doi:10.1038/cddis.2011.123 · Cited by 385
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Targeting glucose metabolism for cancer therapy
Hamanaka, R. B., & Chandel, N. S. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120162 · Cited by 369
Ko, Y. H., Pedersen, P. L., & Geschwind, J. F. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00667-x · Cited by 347
Robinson, M. M., Mcbryant, S. J., Tsukamoto, T., Rojas, C., Ferraris, D. V., Hamilton, S. K., Hansen, J. C., & Curthoys, N. P. (2007) · Biochemical Journal · doi:10.1042/bj20070039 · Cited by 340
Lu, C.-W., Lin, S.-C., Chen, K.-F., Lai, Y.-Y., & Tsai, S.-J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803508200 · Cited by 331
Menendez, J. A., Vellon, L., Mehmi, I., Oza, B. P., Ropero, S., Colomer, R., & Lupu, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403390101 · Cited by 327
The Warburg effect and its cancer therapeutic implications
Chen, Z., Lu, W., Garcia-Prieto, C., & Huang, P. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9086-x · Cited by 318
Glycolysis in cancer: A potential target for therapy
Gatenby, R. A., & Gillies, R. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.021 · Cited by 304
Overcoming Trastuzumab Resistance in Breast Cancer by Targeting Dysregulated Glucose Metabolism
Zhao, Y., Liu, H., Liu, Z., Ding, Y., LeDoux, S. P., Wilson, G. L., Voellmy, R., Lin, Y., Lin, W., Nahta, R., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0127 · Cited by 289
Self-citationZhao, Y. H., Zhou, M., Liu, H., Ding, Y., Khong, H. T., Yu, D., Fodstad, O., & Tan, M. (2009) · Oncogene · doi:10.1038/onc.2009.229 · Cited by 269
Self-citationPizer, E. S., Chrest, F. J., DiGiuseppe, J. A., & Han, W. F. (1998) · PubMed · Cited by 250
Kurtoglu, M., Gao, N., Shang, J., Maher, J. C., Lehrman, M. A., Wangpaichitr, M., Savaraj, N., Lane, A. N., & Lampidis, T. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0310 · Cited by 239
Xie, H., Valera, V. A., Merino, M. J., Amato, A. M., Signoretti, S., Linehan, W. M., Sukhatme, V. P., & Seth, P. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1049 · Cited by 233
Sun, R. C., Fadia, M., Dahlstrom, J. E., Parish, C. R., Board, P. G., & Blackburn, A. C. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0435-9 · Cited by 226
Cao, X., Fang, L., Gibbs, S., Huang, Y., Dai, Z., Wen, P., Zheng, X., Sadee, W., & Sun, D. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0291-9 · Cited by 221
Kato, M., Li, J., Chuang, J. L., & Chuang, D. T. (2007) · Structure · doi:10.1016/j.str.2007.07.001 · Cited by 221
Dichloroacetate induces apoptosis in endometrial cancer cells
Wong, J. Y. Y., Huggins, G. S., Debidda, M., Munshi, N. C., & De Vivo, I. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.038 · Cited by 219
Liu, H., Liu, Y., & Zhang, J.-T. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0445 · Cited by 216
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells
Hulleman, E., Kazemier, K. M., Holleman, A., VanderWeele, D. J., Rudin, C. M., Broekhuis, M. J. C., Evans, W. E., Pieters, R., & Den Boer, M. L. (2009) · Blood · doi:10.1182/blood-2008-05-157842 · Cited by 213
Maher, J. C., Krishan, A., & Lampidis, T. J. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0724-7 · Cited by 204
Sugar-free approaches to cancer cell killing
El Mjiyad, N., Caro-Maldonado, A., Ramírez-Peinado, S., & Muñoz-Pinedo, C. (2011) · Oncogene · doi:10.1038/onc.2010.466 · Cited by 198
McBrayer, S. K., Cheng, J. C., Singhal, S., Krett, N. L., Rosen, S. T., & Shanmugam, M. (2012) · Blood · doi:10.1182/blood-2011-09-377846 · Cited by 192
BCL-xL Is a Target Gene Regulated by Hypoxia-inducible Factor-1α
Chen, N., Chen, X., Huang, R., Zeng, H., Gong, J., Meng, W., Lu, Y., Zhao, F., Wang, L., & Zhou, Q. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805997200 · Cited by 190
Thupari, J. N., Pinn, M. L., & Kuhajda, F. P. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5146 · Cited by 190
Cao, W., Yacoub, S., Shiverick, K. T., Namiki, K., Sakai, Y., Porvasnik, S., Urbanek, C., & Rosser, C. J. (2008) · The Prostate · doi:10.1002/pros.20788 · Cited by 181
Therapeutic targeting of cancer cell metabolism
Dang, C. V., Hamaker, M., Sun, P., Le, A., & Gao, P. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0730-x · Cited by 181
Inhibition of Fatty Acid Synthase Induces Endoplasmic Reticulum Stress in Tumor Cells
Little, J. L., Wheeler, F. B., Fels, D. R., Koumenis, C., & Kridel, S. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1794 · Cited by 181
Li, J. N., Gorospe, M., Chrest, F. J., Kumaravel, T. S., Evans, M. K., Han, W. F., & Pizer, E. S. (2001) · PubMed · Cited by 166
Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P. L., Evangelisti, C., Ognibene, A., Battistelli, M., Falcieri, E., Melchionda, F., Pession, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1814 · Cited by 166
Min, J.-N., Huang, L., Zimonjic, D. B., Moskophidis, D., & Mivechi, N. F. (2007) · Oncogene · doi:10.1038/sj.onc.1210317 · Cited by 162
Targeting cancer metabolism – aiming at a tumour's sweet-spot
Jones, N. P., & Schulze, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 162
Glutaminase: A Hot Spot For Regulation Of Cancer Cell Metabolism?
Erickson, J. W., & Cerione, R. A. (2010) · Oncotarget · doi:10.18632/oncotarget.208 · Cited by 158
Lu, C.-W., Lin, S.-C., Chien, C., Lin, S., Lee, C., Lin, B.-W., Lee, J., & Tsai, S. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.05.050 · Cited by 156
Pradelli, L. A., Bénéteau, M., Chauvin, C., Jacquin, M. A., Marchetti, S., Muñoz‐Pinedo, C., Auberger, P., Pende, M., & Ricci, J. (2009) · Oncogene · doi:10.1038/onc.2009.448 · Cited by 151
A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2
Knowles, L. M., Axelrod, F., Browne, C. D., & Smith, J. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405061200 · Cited by 146
Geschwind, J.-F. H., Georgiades, C. S., Ko, Y. H., & Pedersen, P. L. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.3.449 · Cited by 141
Piret, J., Minet, E., Cosse, J.-P., Ninane, N., Debacq, C., Raes, M. J., & Michiels, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411858200 · Cited by 137
Coloff, J. L., Macintyre, A. N., Nichols, A., Liu, T., Gallo, C. A., Plas, D. R., & Rathmell, J. C. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4531 · Cited by 137
Calvé, B. L., Rynkowski, M. A., Mercier, M. L., Bruyère, C., Lonez, C., Gras, T., Haibe‐Kains, B., Bontempi, G., Decaestecker, C., Ruysschaert, J., et al. (2010) · Neoplasia · doi:10.1593/neo.10526 · Cited by 135
Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia
Flamant, L., Notte, A., Ninane, N., Raes, M., & Michiels, C. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-191 · Cited by 130
Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region
Raspaglio, G., Filippetti, F., Prislei, S., Penci, R., Maria, I. D., Cicchillitti, L., Mozzetti, S., Scambia, G., & Ferlini, C. (2007) · Gene · doi:10.1016/j.gene.2007.11.015 · Cited by 119
Khaleque, A., Bharti, A. K., Sawyer, D. B., Gong, J., Benjamin, I. J., Stevenson, M. A., & Calderwood, S. K. (2005) · Oncogene · doi:10.1038/sj.onc.1208798 · Cited by 115
Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
Shi, H., Li, D., Zhang, J., Wang, Y., Li, Y., Zhang, H., Wang, X., Mu, B., Wang, W., Ma, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01562.x · Cited by 114
Glycolysis Inhibition Inactivates ABC Transporters to Restore Drug Sensitivity in Malignant Cells
Nakano, A., Tsuji, D., Miki, H., Cui, Q., Sayed, S. M. E., Ikegame, A., Oda, A., Amou, H., Nakamura, S., Harada, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027222 · Cited by 112
Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers.
Yang, Y., Liu, H., Li, Z., Zhao, Z., Yip-Schneider, M., Fan, Q., Schmidt, C. M., Chiorean, E. G., Xie, J., Liang Cheng, C., et al. (2011) · PubMed Central · Cited by 109
Browne, C. D., Hindmarsh, E. J., & Smith, J. W. (2006) · The FASEB Journal · doi:10.1096/fj.05-5404com · Cited by 108
Tong, J., Xie, G., He, J., Li, J., Pan, F., & Liang, H. (2011) · BioMed Research International · doi:10.1155/2011/740564 · Cited by 103
Knowles, L. M., Chen, Y., Osterman, A. L., & Smith, J. W. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803384200 · Cited by 100
Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model
Guo, W., Zhang, Y., Chen, T., Wang, Y., Xue, J., Zhang, Y., Xiao, W., Mo, X., & Lü, Y. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0860-5 · Cited by 99
Wen, W., Ding, J., Sun, W. C., Wu, K., Ning, B., Gong, W., He, G., Huang, S., Ding, X., Yin, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-08-4910 · Cited by 96
Vázquez‐Martín, A., Colomer, R., Brunet, J., & Menéndez, J. A. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.4.769 · Cited by 96
Menéndez, J. A., Vellón, L., & Lupu, R. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2004.09.027 · Cited by 93
Anti-Cancer Drugs Targeting Fatty Acid Synthase (FAS)
Pandey, P. R., Liu, W., Xing, F., et al. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212799972891 · Cited by 92
Yoo, B. C., Ku, J., Hong, S., Shin, Y., Park, S. Y., Kim, H. K., & Park, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11604 · Cited by 87
Emerging Metabolic Targets in Cancer Therapy
Zhao, Y., Liu, H., Riker, A. I., Fodstad, Ø., LeDoux, S. P., Wilson, G. L., & Tan, M. (2010) · Frontiers in bioscience · doi:10.2741/3826 · Cited by 85
Self-citationMenéndez, J. A., Lupu, R., & Colomer, R. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000018409.59448.60 · Cited by 82
Efficient Elimination of Cancer Cells by Deoxyglucose-ABT-263/737 Combination Therapy
Yamaguchi, R., Janssen, E. M., Perkins, G. A., Ellisman, M. H., Kitada, S., & Reed, J. C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024102 · Cited by 80
Mechanisms of Trastuzumab Resistance and Their Clinical Implications
Lan, K., Lu, C., & Yu, D. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1339.026 · Cited by 75
Shin, Y., Yoo, B. C., Hong, Y. S., Chang, H. J., Jung, K. H., Jeong, S., & Park, J. (2009) · Electrophoresis · doi:10.1002/elps.200800806 · Cited by 71
Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson
Birsoy, K., Sabatini, D. M., & Possemato, R. (2012) · Nature Medicine · doi:10.1038/nm.2870 · Cited by 69
HIF-1 as a Target for Cancer Chemotherapy, Chemosensitization and Chemoprevention
Monti, E., & Gariboldi, M. B. (2011) · Current Molecular Pharmacology · doi:10.2174/1874-470211104010062 · Cited by 67
Vazquez-Martin, A., Ropero, S., Brunet, J., Colomer, R., & Menéndez, J. A. (2007) · Oncology Reports · doi:10.3892/or.18.4.973 · Cited by 67
Sullivan, R., & Graham, C. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1090 · Cited by 65
Martinez‐Balibrea, E., Plasencia, C., Ginés, A., Martínez‐Cardús, A., Musulén, E., Aguilera, R., Manzano, J. L., Neamati, N., & Abad, A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0882 · Cited by 63
Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line
Li, S., Ye, F., Cai, W., Hu, H., Hu, P., Ren, H., Zhu, F., & Zhang, D. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22413 · Cited by 62
Greijer, A. E., de Jong, M. C., Scheffer, G. L., Shvarts, A., van Diest, P. J., & van der Wall, E. (2005) · Analytical Cellular Pathology · doi:10.1155/2005/236045 · Cited by 61
Combination of Sulindac and Dichloroacetate Kills Cancer Cells via Oxidative Damage
Ayyanathan, K., Kesaraju, S., Dawson-Scully, K. D., & Weissbach, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039949 · Cited by 60
Kronblad, Å., Hedenfalk, I. A., Nilsson, E., Påhlman, S., & Landberg, G. (2005) · Oncogene · doi:10.1038/sj.onc.1208830 · Cited by 48
Meynet, O., Bénéteau, M., Jacquin, M. A., Pradelli, L. A., Cornille, A., Carlès, M., & Ricci, J. (2011) · Leukemia · doi:10.1038/leu.2011.327 · Cited by 48
Zeng, L., Kizaka‐Kondoh, S., Itasaka, S., Xie, X., Inoue, M., Tanimoto, K., Shibuya, K., & Hiraoka, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00537.x · Cited by 41
Ishiguro, T., Ishiguro, M., Ishiguro, R. H., & Iwai, S. (2012) · Oncology Letters · doi:10.3892/ol.2012.552 · Cited by 39
Pei, G.-T., Wu, C.-W., & Lin, W. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.058 · Cited by 21
Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment
Mayes, P. A., Campbell, L., Ricci, M., Plastaras, J. P., Dicker, D. T., & El‐Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2255 · Cited by 19
Cited by
Advances in Copper Complexes as Anticancer Agents
Santini, C., Pellei, M., Gandin, V., Porchia, M., Tisato, F., & Marzano, C. (2014) · Chemical Reviews · doi:10.1021/cr400135x · Cited by 1,790
Tumor glycolysis as a target for cancer therapy: progress and prospects
Ganapathy-Kanniappan, S., & Geschwind, J.-F. H. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-152 · Cited by 1,395
Targeting Metabolism for Cancer Therapy
Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971
Regulation of pyruvate metabolism and human disease
Gray, L. R., Tompkins, S. C., & Taylor, E. B. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1539-2 · Cited by 947
Li, S.-Y., Cheng, H., Xie, B.-R., Qiu, W.-X., Zeng, J.-Y., Li, C.-X., Wan, S.-S., Zhang, L., Liu, W.-L., & Zhang, X.-Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b02533 · Cited by 780
Metadata
- Authors
- Zhao, Y., Butler, E. B., & Tan, M.
- Venue
- Cell Death & Disease
- Published
- 2013-03-07
- Volume
- 4
- Issue
- 3
- Pages
- e532-e532
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2037679360
- Cited by
- 989
- References
- 122
- FWCI
- 33.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.